DK3528838T5 - Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis - Google Patents
Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis Download PDFInfo
- Publication number
- DK3528838T5 DK3528838T5 DK17780280.8T DK17780280T DK3528838T5 DK 3528838 T5 DK3528838 T5 DK 3528838T5 DK 17780280 T DK17780280 T DK 17780280T DK 3528838 T5 DK3528838 T5 DK 3528838T5
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- treatment
- atopic dermatitis
- atopic
- dermatitis
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title 1
- 201000008937 atopic dermatitis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398713P | 2016-09-23 | 2016-09-23 | |
| US201762527204P | 2017-06-30 | 2017-06-30 | |
| US201762530683P | 2017-07-10 | 2017-07-10 | |
| US201762539037P | 2017-07-31 | 2017-07-31 | |
| PCT/US2017/052891 WO2018057849A1 (en) | 2016-09-23 | 2017-09-22 | Uses of il-13 antagonists for treating atopic dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3528838T3 DK3528838T3 (da) | 2023-08-28 |
| DK3528838T5 true DK3528838T5 (da) | 2024-09-02 |
Family
ID=60020628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17780280.8T DK3528838T5 (da) | 2016-09-23 | 2017-09-22 | Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US11434286B2 (enExample) |
| EP (2) | EP3528838B1 (enExample) |
| JP (1) | JP6995844B2 (enExample) |
| KR (1) | KR102557643B1 (enExample) |
| CN (1) | CN109715201A (enExample) |
| AU (1) | AU2017330405B2 (enExample) |
| CA (1) | CA3031589C (enExample) |
| CY (2) | CY1126255T1 (enExample) |
| DK (1) | DK3528838T5 (enExample) |
| ES (1) | ES2958593T3 (enExample) |
| FI (2) | FI3528838T3 (enExample) |
| FR (1) | FR24C1017I2 (enExample) |
| HR (1) | HRP20231015T1 (enExample) |
| HU (2) | HUE063135T2 (enExample) |
| IL (1) | IL265473B2 (enExample) |
| LT (2) | LT3528838T (enExample) |
| MX (1) | MX2019002672A (enExample) |
| NL (1) | NL301269I2 (enExample) |
| NZ (1) | NZ790629A (enExample) |
| PL (1) | PL3528838T3 (enExample) |
| PT (1) | PT3528838T (enExample) |
| RS (1) | RS64550B1 (enExample) |
| RU (1) | RU2752785C2 (enExample) |
| SG (1) | SG11201900845YA (enExample) |
| SI (1) | SI3528838T1 (enExample) |
| TW (1) | TWI787203B (enExample) |
| UA (1) | UA124269C2 (enExample) |
| WO (1) | WO2018057849A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3448391T3 (fi) | 2016-04-27 | 2024-06-19 | Abbvie Mfg Management Unlimited Company | Sellaisten sairauksien hoitomenetelmät, joissa IL-13-aktiviteetti on haitallinen, käyttämällä anti-IL-13-vasta-aineita |
| NZ790629A (en) * | 2016-09-23 | 2025-11-28 | Genentech Inc | Uses of il-13 antagonists for treating atopic dermatitis |
| WO2021191220A1 (en) * | 2020-03-23 | 2021-09-30 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| JP2021147383A (ja) * | 2020-03-23 | 2021-09-27 | メドイミューン・リミテッドMedImmune Limited | アトピー性皮膚炎及び関連障害を処置するための方法 |
| KR20230084166A (ko) * | 2020-10-09 | 2023-06-12 | 쿄와 기린 가부시키가이샤 | Ox40 관련 질환을 치료하는 방법 |
| CA3208011A1 (en) * | 2021-03-17 | 2022-09-22 | Sarah Harris | Methods of treating atopic dermatitis with anti il-13 antibodies |
| TWI847170B (zh) * | 2021-07-16 | 2024-07-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
| TWI859566B (zh) * | 2021-08-13 | 2024-10-21 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
| KR20250005040A (ko) * | 2021-09-15 | 2025-01-09 | 더미라, 인코포레이티드 | 결절성 양진의 치료를 위한 il-13 억제제 |
| AU2023265133A1 (en) * | 2022-05-05 | 2024-11-21 | Dermira, Inc. | Il-13 antibodies for the treatment of atopic dermatitis |
| CA3252634A1 (en) | 2022-06-17 | 2023-12-21 | Apogee Therapeutics, Inc. | ANTIBODIES BINDING TO INTERLEUKIN 13 AND METHODS OF USE |
| JP2025530181A (ja) * | 2022-09-06 | 2025-09-11 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 皮膚炎患者における不眠または睡眠障害の治療 |
| AU2024235509A1 (en) | 2023-03-14 | 2025-09-18 | Geovista Inc. | Antibody specifically binding to interleukin-13, and use thereof |
| KR102773781B1 (ko) | 2023-03-14 | 2025-02-28 | 주식회사 지오비스타 | 인터루킨-13에 특이적으로 결합하는 항체 및 그의 용도 |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
| KR20250017610A (ko) | 2023-07-27 | 2025-02-04 | 김천균 | 아토피의 치료와 예방용 조성물 및 그 제조방법 |
| TW202525846A (zh) | 2023-08-25 | 2025-07-01 | 美商普羅特歐拉吉克適美國公司 | 抗ｉｌ—１３多特異性抗體構築體及其用途 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| WO2025155874A1 (en) * | 2024-01-18 | 2025-07-24 | Enveda Therapeutics, Inc. | Methods and compounds for modulating immune response |
| WO2025264972A1 (en) * | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-4r alpha and antibodies that bind |
| WO2025264960A1 (en) * | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-13 and antibodies that bind ox40l |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| AU3369999A (en) | 1998-04-02 | 1999-10-25 | Genentech Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| PT1222292E (pt) | 1999-10-04 | 2005-11-30 | Medicago Inc | Metodo para regulacao da transcricao de genes exogenos na presenca de azoto |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002043478A2 (en) | 2000-11-30 | 2002-06-06 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| JPWO2003085119A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| NZ556507A (en) | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
| NO347530B1 (no) | 2003-11-05 | 2023-12-11 | Roche Glycart Ag | Et humanisert type II anti-CD20 antistoff og vertscelle som produserer et humanisert type II anti-CD20 antistoff samt en fremgangsmåte for fremstilling og en farmasøytisk sammensetning. |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| CN1898264A (zh) * | 2003-12-23 | 2007-01-17 | 泰勒公司 | 用新的抗il13单克隆抗体治疗癌症 |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| CN1942483B (zh) | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| DK1814615T3 (en) | 2004-11-24 | 2016-01-11 | Shl Group Ab | Injection device |
| US7896850B2 (en) | 2005-06-01 | 2011-03-01 | Telefonaktiebolaget L M Ericsson (Publ) | Device for delivering medicament |
| ES2314568T3 (es) | 2005-06-01 | 2009-03-16 | Shl Group Ab | Dispositivo para la entrega de medicamento. |
| JP2009510046A (ja) | 2005-09-30 | 2009-03-12 | メドイミューン・リミテッド | インターロイキン−１３抗体組成物 |
| KR20130020850A (ko) * | 2005-10-21 | 2013-02-28 | 노파르티스 아게 | Ｉｌ-13에 대항한 인간 항체 및 치료적 용도 |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| MX2009007406A (es) | 2007-01-09 | 2010-01-25 | Wyeth Corp | Formulaciones de anticuerpo anti-il-13 y usos de las mismas. |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| EP2652498B1 (en) | 2010-12-16 | 2018-04-18 | F.Hoffmann-La Roche Ag | Diagnosis and treatments relating to th2 inhibition |
| AU2013204900B2 (en) * | 2010-12-16 | 2016-11-10 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
| JP5814465B2 (ja) | 2011-06-17 | 2015-11-17 | エス・ホー・エル・グループ・アクチボラゲットＳｈｌ Ｇｒｏｕｐ Ａｂ | 注射装置 |
| CA2839496C (en) | 2011-06-17 | 2016-02-09 | Shl Group Ab | Injection device |
| SG11201401903PA (en) * | 2011-10-31 | 2014-05-29 | Genentech Inc | Antibody formulations |
| ES2981062T3 (es) | 2012-09-07 | 2024-10-07 | Regeneron Pharma | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| KR20150139905A (ko) | 2013-04-05 | 2015-12-14 | 제넨테크, 인크. | 항-il-4 항체 및 이중특이적 항체 및 그의 용도 |
| US20160363591A1 (en) * | 2014-01-27 | 2016-12-15 | Medimmune, Llc | Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung |
| WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
| NZ790629A (en) * | 2016-09-23 | 2025-11-28 | Genentech Inc | Uses of il-13 antagonists for treating atopic dermatitis |
-
2017
- 2017-09-22 NZ NZ790629A patent/NZ790629A/en unknown
- 2017-09-22 ES ES17780280T patent/ES2958593T3/es active Active
- 2017-09-22 WO PCT/US2017/052891 patent/WO2018057849A1/en not_active Ceased
- 2017-09-22 PT PT177802808T patent/PT3528838T/pt unknown
- 2017-09-22 MX MX2019002672A patent/MX2019002672A/es unknown
- 2017-09-22 AU AU2017330405A patent/AU2017330405B2/en active Active
- 2017-09-22 UA UAA201902409A patent/UA124269C2/uk unknown
- 2017-09-22 PL PL17780280.8T patent/PL3528838T3/pl unknown
- 2017-09-22 RS RS20230712A patent/RS64550B1/sr unknown
- 2017-09-22 HR HRP20231015TT patent/HRP20231015T1/hr unknown
- 2017-09-22 CA CA3031589A patent/CA3031589C/en active Active
- 2017-09-22 IL IL265473A patent/IL265473B2/en unknown
- 2017-09-22 LT LTEPPCT/US2017/052891T patent/LT3528838T/lt unknown
- 2017-09-22 TW TW106132523A patent/TWI787203B/zh active
- 2017-09-22 KR KR1020197007162A patent/KR102557643B1/ko active Active
- 2017-09-22 FI FIEP17780280.8T patent/FI3528838T3/fi active
- 2017-09-22 SI SI201731388T patent/SI3528838T1/sl unknown
- 2017-09-22 EP EP17780280.8A patent/EP3528838B1/en active Active
- 2017-09-22 CN CN201780058200.4A patent/CN109715201A/zh active Pending
- 2017-09-22 RU RU2019103943A patent/RU2752785C2/ru active
- 2017-09-22 HU HUE17780280A patent/HUE063135T2/hu unknown
- 2017-09-22 JP JP2019515636A patent/JP6995844B2/ja active Active
- 2017-09-22 EP EP23182855.9A patent/EP4268845A3/en active Pending
- 2017-09-22 DK DK17780280.8T patent/DK3528838T5/da active
- 2017-09-22 SG SG11201900845YA patent/SG11201900845YA/en unknown
-
2019
- 2019-03-18 US US16/356,309 patent/US11434286B2/en active Active
-
2022
- 2022-08-08 US US17/882,932 patent/US20220372131A1/en active Pending
-
2023
- 2023-09-13 CY CY20231100495T patent/CY1126255T1/el unknown
-
2024
- 2024-03-21 US US18/612,141 patent/US20240228606A1/en active Pending
- 2024-04-29 LT LTPA2024512C patent/LTC3528838I2/lt unknown
- 2024-04-29 NL NL301269C patent/NL301269I2/nl unknown
- 2024-04-29 FR FR24C1017C patent/FR24C1017I2/fr active Active
- 2024-04-30 FI FIC20240013C patent/FIC20240013I1/fi unknown
- 2024-04-30 HU HUS2400011C patent/HUS2400011I1/hu unknown
- 2024-05-29 CY CY2024013C patent/CY2024013I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3528838T5 (da) | Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis | |
| EP3426686C0 (en) | Humanized Anti-PACAP Antibodies and Their Uses | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| LT3280441T (lt) | Anti-sortilino antikūnai ir jų naudojimo būdai | |
| LT3258951T (lt) | Anti-pvrig antikūnai ir jų panaudojimo būdai | |
| DK3253865T3 (da) | Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller | |
| IL246693B2 (en) | Antibody molecules to tim-3 and uses thereof | |
| IL258245A (en) | Anti-variant fc-region antibodies and methods of use | |
| LT3215532T (lt) | Anti-tim3 antikūnai ir jų naudojimo būdai | |
| DK3248986T3 (da) | Variable immunoglobulindomæner | |
| LT3148579T (lt) | Anti-gitr antikūnai ir jų panaudojimo būdai | |
| LT3303394T (lt) | Anti-ctla-4 antikūnai ir jų naudojimo būdai | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| LT3250610T (lt) | Fcrn antikūnai ir jų panaudojimo būdai | |
| FR3018941B1 (fr) | Pilotage de vehicules en convoi | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| IL247002A0 (en) | Anti-il-17/il-13 bispecific antibodies and their uses | |
| EP3835319C0 (en) | Humanized Anti-ACTH Antibodies and Their Use | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| LT3491025T (lt) | Fcrn antikūnai ir jų panaudojimo būdai | |
| DK4339615T3 (da) | Anti-PD-1-antistof til anvendelse i behandlingen af kræft | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose |